Loring Wolcott & Coolidge Fiduciary Advisors LLP Novavax Inc Transaction History
Loring Wolcott & Coolidge Fiduciary Advisors LLP
- $10.3 Billion
- Q1 2025
A detailed history of Loring Wolcott & Coolidge Fiduciary Advisors LLP transactions in Novavax Inc stock. As of the latest transaction made, Loring Wolcott & Coolidge Fiduciary Advisors LLP holds 570 shares of NVAX stock, worth $4,257. This represents 0.0% of its overall portfolio holdings.
Number of Shares
570
Previous 570
-0.0%
Holding current value
$4,257
Previous $4,000
25.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding NVAX
# of Institutions
309Shares Held
90.6MCall Options Held
5.76MPut Options Held
6.65M-
Vanguard Group Inc Valley Forge, PA15.7MShares$117 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.8MShares$88.5 Million0.0% of portfolio
-
Shah Capital Management11.5MShares$86 Million35.13% of portfolio
-
State Street Corp Boston, MA7.04MShares$52.6 Million0.0% of portfolio
-
Coatue Management LLC New York, NY3.84MShares$28.7 Million0.13% of portfolio
About NOVAVAX INC
- Ticker NVAX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,215,104
- Market Cap $584M
- Description
- Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...